Kissei Pharmaceutical Co., Ltd. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027

Overview of Results

This financial summary reports consolidated results for the second quarter of the fiscal year ending March 2027. Net sales were 45,503 million yen (Year-over-Year -0.7%), operating income was 1,694 million yen, ordinary income was 2,923 million yen, and interim net income attributable to owners of parent was 5,191 million yen (Year-over-Year -33.3%). Segment contributions for the interim period were primarily driven by the pharmaceutical business. The full-year earnings forecast assumes net sales of 89,000 million yen and net income of 10,000 million yen, but note that revisions upward or downward are possible given impacts including special gains/losses related to Tabneos.

Outlook and Capital Policy Background

The current environment remains challenging due to factors such as drug price revisions, and exchange rate and interest rate movements may affect performance. The full-year forecast for the fiscal year ending March 2027 will be revised after reassessing Tabneos prospects, combining reductions and increases focused on certain products. The financial summary also explains share-related actions, such as treasury stock acquisitions and disposal of restricted shares, and the financial position remains solid with a shareholders' equity ratio of 85.5%.